ArticleNanoscale2015
Leveraging electrokinetics for the active control of dendritic fullerene-1 release across a nanochannel membrane.
Article in Nanoscale, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Sensing and Stimulation Applications of Carbon Nanomaterials in Implantable Brain-Computer Interface.International journal of molecular sciences · 2023Review
- Advances in Pain Medicine: a Review of New Technologies.Current pain and headache reports · 2022Review
- Silicon Carbide-Gated Nanofluidic Membrane for Active Control of Electrokinetic Ionic Transport.Membranes · 2021Article
- Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery.Lab on a chip · 2020Article
- Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases.Biomedical microdevices · 2019Review
- Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Gas Flow at the Ultra-nanoscale: Universal Predictive Model and Validation in Nanochannels of Ångstrom-Level Resolution.ACS applied materials & interfaces · 2018Article
- Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale.Nature communications · 2018Article
- The active modulation of drug release by an ionic field effect transistor for an ultra-low power implantable nanofluidic system.Nanoscale · 2016Article
- The Emerging Role of Nanotechnology in Cell and Organ Transplantation.Transplantation · 2016Review
- Sustained Administration of Hormones Exploiting Nanoconfined Diffusion through Nanochannel Membranes.Materials (Basel, Switzerland) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
General adoption of advanced treatment protocols such as chronotherapy will hinge on progress in drug delivery technologies that provide precise temporal control of therapeutic release. Such innovation is also crucial to future medicine approaches such as telemedicine. Here we present a nanofluidic membrane technology capable of achieving active and tunable control of molecular transport through nanofluidic channels. Control was achieved through application of an electric field between two platinum electrodes positioned on either surface of a 5.7 nm nanochannel membrane designed for zero-order drug delivery. Two electrode configurations were tested: laser-cut foils and electron beam deposited thin-films, configurations capable of operating at low voltage (≤1.5 V), and power (100 nW). Temporal, reproducible tuning and interruption of dendritic fullerene 1 (DF-1) transport was demonstrated over multi-day release experiments. Conductance tests showed limiting currents in the low applied potential range, implying ionic concentration polarization (ICP) at the interface between the membrane's micro- and nanochannels, even in concentrated solutions (≤1 M NaCl). The ability of this nanotechnology platform to facilitate controlled delivery of molecules and particles has broad applicability to next-generation therapeutics for numerous pathologies, including autoimmune diseases, circadian dysfunction, pain, and stress, among others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.